Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.

Three healthcare sector leaders, Johnson & Johnson (JNJ), AbbVie (ABBV), and UnitedHealth Group (UNH), are presented as compelling dividend investment opportunities for their consistent payouts and growth prospects. JNJ, a Dividend King with 62 years of raises, offers a 3.3% yield and strong financials, with its current 14x earnings valuation potentially reflecting a buying opportunity despite ongoing talcum powder litigation. AbbVie provides a 3.7% yield and 7.8% dividend growth, underpinned by a diversified pharmaceutical pipeline and projected >7% annual earnings growth. UnitedHealth Group, a dominant healthcare conglomerate, delivers a 1.7% yield with significant >16% dividend growth over five years, driven by market expansion and a low 30% payout ratio, supported by analyst forecasts of >12% earnings growth.

Analysis

The healthcare sector presents compelling opportunities for dividend-focused investors, with industry leaders Johnson & Johnson (JNJ), AbbVie (ABBV), and UnitedHealth Group (UNH) demonstrating robust financial health and consistent capital returns. JNJ, a Dividend King with 62 consecutive years of dividend increases, offers a 3.3% starting yield and a conservative 47% payout ratio against estimated 2024 earnings, underpinned by its diverse product portfolio and highest available credit rating. Its current valuation at 14 times earnings, influenced by ongoing talcum powder litigation, may represent a strategic entry point, as settlements are expected to be manageable over time without threatening the dividend.

AbbVie provides a higher starting yield of 3.7% and a strong three-year average dividend growth of 7.8%, supported by a 55% payout ratio. Despite the patent expiry of its blockbuster drug Humira, the company's diversified pharmaceutical pipeline, including Botox and new drug developments, positions it for continued growth, with analysts forecasting over 7% annual earnings growth for the next three to five years. This indicates a sustainable path for future dividend increases.

UnitedHealth Group, a dominant force in the U.S. healthcare system, exhibits exceptional dividend growth, averaging over 16% annually for the past five years, despite a lower 1.7% starting yield. Its massive scale, $380 billion in annual revenue, and competitive advantage in delivering cost-effective services drive consistent double-digit revenue growth and market share expansion. With a very low 30% payout ratio and analyst projections for over 12% annual earnings growth, UNH is well-positioned for sustained double-digit dividend raises.

Collectively, these companies offer a blend of stability, income, and growth within the resilient healthcare industry. Their strong fundamentals, disciplined financial management, and favorable analyst outlooks suggest continued dividend excellence, making them attractive for institutional investors seeking long-term value and income generation.

Key Decisions for Investors

• Consider initiating or increasing exposure to Johnson & Johnson, leveraging its Dividend King status and strong balance sheet, particularly given its current valuation potentially depressed by litigation concerns which are unlikely to impact dividend sustainability.
• Evaluate AbbVie for its attractive combination of a higher current dividend yield and robust growth prospects, supported by a diversifying product pipeline and strong projected earnings growth.
• Assess UnitedHealth Group for its aggressive dividend growth trajectory and market leadership, recognizing its lower initial yield is offset by significant capital appreciation potential and a very conservative payout ratio.
• Monitor the payout ratios and analyst earnings growth forecasts for all three companies as key indicators for the sustainability and future growth of their dividend payments.